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Electrons utilized in the heme oxygenase (HO) reaction are
provided by NADPH-cytochrome P450 reductase (CPR). To
investigate the electron transfer pathway from CPR to HO, we
examined the reactions of heme and verdoheme, the second
intermediate in the heme degradation, complexed with rat
HO-1 (rHO-1) using a rat FMN-depleted CPR; the FMN-de-
pleted CPR was prepared by dialyzing the CPRmutant, Y140A/
Y178A, against 2 M KBr. Degradation of heme in complex with
rHO-1 did not occur with FMN-depleted CPR, notwithstanding
that the FMN-depleted CPR was able to associate with the
heme-rHO-1 complex with a binding affinity comparable with
that of the wild-type CPR. Thus, the first electron to reduce the
ferric iron of heme complexed with rHO-1 must be transferred
from FMN. In contrast, verdoheme was converted to the ferric
biliverdin-iron chelate with FMN-depleted CPR, and this con-
version was inhibited by ferricyanide, indicating that electrons
are certainly required for conversion of verdoheme to a ferric
biliverdin-iron chelate and that they can be supplied from the
FMN-depleted CPR through a pathway not involving FMN,
probably via FAD. This conclusion was supported by the obser-
vation that verdoheme dimethyl esters were accumulated in the
reaction of the ferriprotoporphyrin IX dimethyl ester-rHO-1
complex with the wild-type CPR. Ferric biliverdin-iron chelate,
generated with the FMN-depleted CPR, was converted to biliv-
erdin by the addition of the wild-type CPR or desferrioxamine.
Thus, the final electron for reducing ferric biliverdin-iron che-
late to release ferrous iron and biliverdin is apparently provided
by the FMN of CPR.
Heme oxygenase (HO4; EC 1.14.99.3) is a microsomal
enzyme that catalyzes the degradation of heme to biliverdin
IX, carbon monoxide (CO), and free iron in the presence of
NADPH-cytochrome P450 reductase (CPR; EC 1.6.2.4) (1–3).
TheHO reaction proceeds via amultistepmechanism as shown
in Fig. 1 (4, 5). The first step is the oxidation of heme to -hy-
droxyheme, requiring molecular oxygen (O2) and reducing
equivalents supplied by CPR (6–8). The second step is the for-
mation of verdohemewith the concomitant release of hydroxy-
lated -meso carbon as CO (9–11). The third step is the con-
version of -verdoheme to a biliverdin-iron chelate, for which
O2 and electrons from CPR are also required (12). In the last
step, the iron of the biliverdin-iron chelate is reduced, and
finally ferrous iron and biliverdin are released from HO. The
conversion of verdoheme to the ferric biliverdin-iron chelate
along with the release of biliverdin is a rate-limiting step in the
HO reaction (13). The mechanism of degradation of ver-
doheme is the least understood of the three successive oxygen-
ation reactions during the HO catalysis, although some chem-
ical mechanisms have been proposed (12, 14).
CPR is an FAD- and FMN-containing protein that supplies
electrons required for the HO reaction as well as for a variety of
other hemoproteins, such as cytochrome P450s and cyto-
chrome b5. With the latter hemoproteins, it is thought that
electrons fromNADPH flow first to FAD and then to FMN and
finally to their heme groups (15–17). For electron transfer, CPR
and its redox partners need to associate with each other.
Indeed, the molecular surface of HO-1 surrounding the
exposed -meso edge of heme is positively charged and can
form an electrostatic complex with the negatively charged sur-
face of CPR (18).
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Recently, using site-specificmutation and dockingmodeling,
we have found that Arg185 and Lys149 of rat HO-1 (rHO-1) are
important in both the HO activity and its association with CPR
(19). In ourmodel, the guanidino group ofArg185 interacts elec-
trostatically with 2-phosphate of NADPH in CPR, whereas
Lys149 is close to a cluster of acidic amino acids near the FMN
binding site of CPR (Fig. 2). Thus, Arg185 and Lys149 appear to
interact with CPR in such a way as to orient the redox partners
for optimal electron transfer from the FMNof CPR to the heme
ofHO-1. Themodel also suggested that the electrons fromCPR
are transferred through the distal side of the heme pocket to
heme and that Lys149 is involved in the electron transfer from
FMN. However, Arg185 appeared not to be involved in electron
transfer from FMN, since its location is far from the FMNbind-
ing site of CPR.
Thus far, crystal structures of rat and/or human HO-1 in the
heme-free (20, 21), heme-bound (22, 23), verdoheme-bound
(14), biliverdin-iron chelate-bound (24), and biliverdin-bound
forms (25) have been reported. In particular, the crystal struc-
ture of the heme-bound form (heme-HO-1 complex) revealed
that the highly conserved Lys179 and Arg183 residues interact
electrostatically with the heme propionate groups and that
these residues play important roles in the -regiospecificity of
HO catalysis (22, 23, 26). The necessity of the heme propionate
side chains at theC-6 andC-7 positions for theHO reaction has
been also suggested from previous studies on the substrate
specificity of HO using a variety of modified hemes (27, 28).
Specifically, a modified heme, in which the C-6 and C-7 propi-
onates are substituted with butyrates, can be degraded to bili-
rubin at only half the rate observedwith the normal hemeunder
the usual HO reaction conditions
containing CPR and biliverdin
reductase, whereas the heme modi-
fied with acetates cannot serve as a
substrate for HO. Furthermore, it
has been shown that the catalytic
activity of the R183E mutant of
human HO-1 was decreased to only
2–3% that of the wild-type enzyme
in the NADPH/CPR-supported
reaction (yielding 100% of -iso-
mer), whereas no significant de-
crease of activity was observed in
the ascorbate-supported reaction
(yielding 80% -isomer and 20%
-isomer) (29, 30). In parallel with
this, the electron transfer rate from
CPR was drastically decreased with
the R183E mutant (31). These facts
suggest that the electrostatic inter-
action between Arg183 of HO and
the heme propionates may play an
important role not only in the -re-
giospecificity of the HO catalysis
but also in electron transfer
between CPR and HO.
In order to shed light on the
electron transfer mechanism from
CPR to HO and also to explore how the interactions between
the basic residues, Lys179 and Arg183, and the heme propi-
onates are involved in the electron transfer, we prepared a
rat FMN-depleted CPR and compared the degradation of
heme, verdoheme, and ferriprotoporphyrin IX dimethyl
ester (FePPDME) complexed with rHO-1 using the wild-
type CPR and the FMN-depleted CPR. Here we present evi-
dence that the FMN-depleted CPR can support the conversion
of verdoheme to the ferric biliverdin-iron chelate, indicating
that electrons required for verdoheme oxidation can be trans-
ferred through a pathway not involving FMN.
EXPERIMENTAL PROCEDURES
Materials—FAD, NADPH, hemin, hexafluoroacetone, des-
ferrioxamine, potassium ferricyanide, and cytochrome c were
purchased from Sigma; FMN and sodium ascorbate were from
Nacalai Tesque (Kyoto, Japan); and FePPDME was from Fron-
tier Scientific (Logan, UT). Bymatrix-assisted laser desorption/
ionization time-of-flight mass spectrometry analysis, it was
confirmed that the FePPDME (m/z 644.4 found, 644.2 calc) did
not contain unesterified hemin. -Verdoheme (hereafter
referred to as verdoheme) was synthesized and purified as
reported earlier (10). Formation of verdoheme was confirmed
by its optical absorption spectrum (max in aqueous pyridine
solution: 397, 505, 534, and 680 nm). Concentration of the
bispyridine complex of verdoheme was determined spectro-
photometrically using 397  53.3 mM1 cm1 (10). All spec-
trophotometric analyses were conducted on a Varian Cary 50
Bio UV-visible spectrophotometer at room temperature or at
the temperatures indicated.
FIGURE 1. Oxidative degradation of heme catalyzed by HO. HO catalyzes the degradation of heme to
biliverdin IX through three distinct intermediates, -hydroxyheme, -verdoheme, and biliverdin-iron che-
late, at the expense of O2 and reducing equivalents.
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Preparation of Heme-rHO-1, Verdoheme-rHO-1, and FePP-
DME-rHO-1 Complexes—A soluble form of rHO-1 lacking the
22-amino acid C-terminal hydrophobic segment was expressed
in Escherichia coli and purified as described previously (32).
The ferric heme complex of rHO-1 was reconstituted with 1.2
eq of heme and purified by column chromatography on
hydroxyapatite (Bio-Rad) as previously described (32).
The reconstitution and purification of the verdoheme-
rHO-1 complex were performed as reported previously (10).
Briefly, to the rHO-1 solution (0.1 mM) in 0.1 M potassium
phosphate, pH7.4, was added a slight excess of verdoheme as an
aqueous pyridine solution. The mixture was incubated at 4 °C
for 1 h and then passed through a Sephadex G-25 gel filtration
column. The purified ferrous verdoheme-rHO-1 complex
exhibited absorptionmaxima at 399 nm ( 50.2 mM1 cm1)
and 534 and 688 nm with an A399 nm/A280 nm value of 1.1 (12).
The reconstitution and purification of the FePPDME-rHO-1
complex were carried out in a similar manner. To the rHO-1
solution (1 M) in 0.1 M potassium phosphate, pH 7.4, was
added a slight excess of FePPDME dissolved in pyridine. The
mixture was kept on ice for 30 min, and the FePPDMErHO-1
complex was purified by column chromatography on hydroxy-
apatite. Fractions containing the complexwere pooled and con-
centrated by ultrafiltration. The approximate concentration of
FePPDME-rHO-1 complex was estimated employing   140
mM1 cm1 of the Soret band of ferric heme-rHO-1 complex
(33).
Preparation of Wild-type CPR
and Its Y140A/Y178A Mutant—A
recombinant rat liver CPR lacking
the N-terminal 57 hydrophobic
amino acids, called wild-type CPR
in this study, was expressed and
purified as previously described
(34). The CPR mutant, Y140A/
Y178A, was generated from the
wild type with the Stratagene
QuikChange site-directed muta-
genesis kit (Stratagene, La Jolla,
CA). The mutations were confirmed
byDNA sequencing. The homogene-
ity of the purified enzymes was deter-
mined by SDS-PAGE.
Preparation and Characteriza-
tion of FMN-depleted CPR—FMN-
depleted CPR was prepared from
the Y140A/Y178A mutant, taking
advantage of the KBr method
reported in Ref. 35. The Y140A/
Y178A mutant was dialyzed over-
night, with one change of the buffer
solution, against 2 M KBr in 0.05 M
potassium pyrophosphate buffer,
pH 8.5, containing 10% glycerol.
The KBr-treated mutant was then
dialyzed overnight against 0.02 M
potassiumphosphate buffer, pH 7.7,
to remove the KBr. The flavin con-
tents in CPR were determined by HPLC with minor modifica-
tions of the procedure of Kurzban and Strobel (36). The
reductase was denatured by dilution into 3 volumes of satu-
rated guanidine hydrochloride. HPLC was carried out on a
Waters model 600E multisolvent delivery system equipped
with a Waters 996 photodiode array detector, a Waters 776
auto sampler, and Millennium software (Millipore Corp.,
Bedford, MA). A 5C18-MS-II (4.6  250 mm) column
obtained from Nacalai Tesque was used. Elution was con-
ducted using a 40-ml linear gradient from water containing
0.05% trifluoroacetic acid to acetonitrile containing 0.04%
trifluoroacetic acid at a flow rate of 1 ml/min and was mon-
itored at 450 nm. Flavines were quantified by peak area based
on the standard curves constructed with authentic FAD or
FMN.
Measurement of cytochrome c-reducing activity of CPR was
carried out at 28 °Cwith a reactionmixture of 0.27 M potassium
phosphate, pH 7.7, 50 MNADPH, and 65 M cytochrome c in
a final volume of 1.0ml (37). The ferricyanide-reducing activity
of CPR was measured at 28 °C with a reaction mixture of 0.3 M
potassium phosphate, pH 7.7, 100 M NADPH, and 500 M
potassium ferricyanide in a final volume of 1.0 ml (36). The
binding affinity of the heme-rHO-1 complex with CPR was
determined by surface plasmon resonance technology using a
BIAcore 1000 instrument (BIAcore AB, Uppsala, Sweden), as
described previously (19).
FIGURE 2. Diagram of the critical amino acids surrounding the cofactor binding sites at the interface
betweenCPRand theheme-rHO-1complex (19).HO-1andCPRare representedaspurple- andgreen-colored
tubes, respectively. The side chains of residues are shown as sticks (carbon inwhite, oxygen in red, and nitrogen
in light blue). NADP (phosphorus in yellow), FAD, and FMN are shown bymagenta sticks, and heme is shown by
the ball-and-sticks (orange).
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Single Turnover HO Reaction of Heme-rHO-1, Verdoheme-
rHO-1, and FePPDME-rHO-1 Complexes—All single turnover
reactions were monitored by optical absorption changes at
25 °C. Unless otherwise indicated, the reaction mixtures (0.1
ml) consisted of 5Mheme-, verdoheme-, or FePPDME-rHO-1
complex, a 0.04–0.4 M concentration of the wild-type or
FMN-depleted CPR, and 25 M NADPH in 0.1 M potassium
phosphate buffer, pH 7.4. Spectra were recorded over the range
of 300–900 nm. When ascorbate was employed as the reduc-
tant, 20 mM sodium ascorbate was added in place of the
NADPH/CPR system. The effect of ferricyanide on the single
turnover reaction of the verdoheme-rHO-1 complex (5 M)
was examined with the NADPH (25 M)/FMN-depleted CPR
(100 nM) system in the presence of ferricyanide (0–100 M).
Biliverdin dimethyl ester isomers produced in the single turn-
over reaction of FePPDMErHO-1 complex were analyzed by
HPLC as described previously (10).
RESULTS
Preparation and Characterization of FMN-depleted CPR—
We first tried to prepare an FMN-free CPR by introducing a
double mutation at Tyr140 and Tyr178; these Tyr residues are
known to be responsible for the binding of FMN to CPR (18,
37). Table 1 shows that the replacement of the two Tyr residues
with Ala selectively decreased the FMN content from 1.12 to
0.09 mol/mol of protein, whereas no significant effect on the
FAD content was detected. Dialysis against 2 M KBr (35, 38)
resulted in thorough removal of FMN from the CPR mutant
without affecting the FAD content. Hereafter, the KBr-treated
mutant CPR will be referred to as the FMN-depleted CPR. CD
analysis revealed that the spectrum of the FMN-depleted CPR
was almost identical to that of the wild-type CPR, indicating
that the deletion of FMNproduced almost no effect on the CPR
conformation (supplemental Table S1 and Fig. S1).
We next evaluated the electron transfer activities of the wild-
type and the FMN-depleted CPR using cytochrome c and
potassium ferricyanide as electron acceptors. As shown in
Table 2, the wild-type CPR reduced cytochrome c and ferricya-
nide at rates of 54.8 and 66.7 mol/min/mg protein, respec-
tively. On the other hand, the FMN-depleted CPR almost com-
pletely lost the ability to transfer an electron to cytochrome c
but retained ferricyanide reducing activity comparable with
that of the wild-type CPR. These results are consistent with
previous studies using the FMN-deficient CPRs that were pre-
pared from thewild-typeCPRby theKBr treatment (35, 36, 39).
The possibility that removal of FMN from CPR would cause a
decrease in the binding affinity of CPR for rHO-1 was ruled out
by a surface plasmon resonance analysis; the dissociation con-
stant for binding of heme-rHO-1 complex to the FMN-de-
pletedCPR in the presence ofNADPwas 0.44 0.1M,which
was comparable with that for the wild-type CPR (0.49 0.1M
(19)). Thus, the electron transfer activities of the FMN-depleted
CPR are directly related to its flavin composition.
Single Turnover Reactions of Heme-rHO-1 Complex with
NADPH/Wild-type and FMN-depleted CPR Systems—We first
examined the single turnover reaction of heme-rHO-1 complex
withwild-typeCPR (Fig. 3A). The heme complexedwith rHO-1
changed immediately to the ferrous oxy form, as indicated by
the appearance of the 539- and 576-nm peaks, upon the addi-
tion of NADPH (25 M, 5 eq to heme-rHO-1 complex) and the
wild-type CPR (0.04 M). The ferrous oxy formwas then trans-
formed to biliverdin as indicated by the decrease in the Soret
band and the increase in absorption around 680 nm. The heme
bound to rHO-1 was completely degraded to biliverdin within
30 min under these conditions.
The effect of the NADPH/FMN-depleted CPR system on the
absorption spectrum of the heme-rHO-1 complex is shown in
FIGURE 3. Absorption spectral changes of the heme-rHO-1 complex dur-
ing the NADPH/CPR-supported single turnover reaction. The spectra
were recordedbefore (thin solid line) and after the additionofNADPH (dashed
and dotted line, 1min; dotted line, 5min; dashed line, 10min; thick solid line, 25
min). The procedures are described under “Experimental Procedures.”A, with
wild-type CPR; B, with FMN-depleted CPR.
TABLE 2
Electron transfer activities of wild-type and FMN-depleted CPR
The assay conditions are described under “Experimental Procedures.” The values of
mean S.D. of three independent assays are presented.
Enzyme Cytochrome c Ferricyanide
mol/min/mg protein
Wild-type CPR 54.8 6.0 66.7 6.8
FMN-depleted CPR 0.05 0.02 62.4 7.2
TABLE 1
Quantification of the flavin contents of wild-type CPR and its mutant
by HPLC
CPR FMN FAD
mol/mol protein
Wild-type CPR 1.12 0.90
Y140A/Y178A mutant 0.09 0.87
FMN-depleted CPRa 0.004 0.85
a FMN-depleted CPR was prepared by dialyzing Y140A/Y178A mutant against 2 M
KBr as described under “Experimental Procedures.”
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Fig. 3B. The addition of NADPH (25 M) and the FMN-de-
pleted CPR (0.04 M) to the heme-rHO-1 complex did not
cause any spectral changes except for an absorbance increase
around 340 nm due to NADPH. Even with a 10-fold amount of
the FMN-depleted CPR (0.4 M), no spectral changes were
observed (data not shown). Thus, it could be concluded that the
first electron to reduce the ferric heme iron to the ferrous state
must be transferred from FMN to HO.
Single Turnover Reactions of Verdoheme-rHO-1 Complex
with NADPH/Wild-type and FMN-depleted CPR Systems—We
next compared the degradation of verdoheme complexed with
rHO-1 with wild-type and FMN-depleted CPR. Fig. 4A shows
the changes in absorption spectra during the reaction of the
verdoheme-rHO-1 complex with the NADPH/wild-type CPR
system. Upon the addition of NADPH (25 M) and wild-type
CPR (0.04M), the 399-nm absorption peak of the verdoheme-
rHO-1 complex decreased and shifted to 384nm, and the inten-
sity of the 688-nm peak decreased, leaving a broad absorption
around 680 nm indicative of biliverdin formation. Thus ver-
doheme complexed with rHO-1 was completely degraded to
biliverdin within 30 min under these conditions.
In contrast, upon the addition of
the FMN-depleted CPR (0.04 M)
and NADPH (25 M) to the ver-
doheme-rHO-1 complex, the 399-
and 688-nm absorption peaks
slowly decreased without any shift,
and the absorbance between 800
and 900 nm increased (Fig. 4B). No
additional spectral change was
observed after 60 min, although
about half of the NADPH still
remained in the reaction mixture.
The spectral changes showed three
clear isosbestic points, at 543, 600,
and 708 nm, indicating that no spec-
tral intermediates are present in this
reaction. The final spectrum bore a
close resemblance to that of the fer-
ric biliverdin-iron chelate reported
previously (40). The rate of degrada-
tion of verdoheme in complex with
rHO-1 was calculated from the
decrease of the 399-nm absorbance
of the verdoheme-rHO-1 complex
(  50.2 mM1 cm1) and was
found to be linearly dependent on
the concentration of the FMN-de-
pleted CPR (Fig. 4C).
That the product formed in the
reaction with the FMN-depleted
CPR is ferric biliverdin-iron chelate
was confirmedby the addition of the
ferric iron chelator desferrioxamine
to the 60-min reactionmixture (Fig.
5A). The absorbance between 800
and 900 nm was decreased, and the
384-nm absorption peak and the
broad band around 670 nm appeared with well defined isos-
bestic points at 585 and 750 nm, indicative of free biliverdin
formation.When thewild-typeCPR (0.04M)was added to the
60-min reaction mixture, the spectral changes observed were
identical to those with desferrioxamine (Fig. 5B). Furthermore,
we investigated the effect of ferricyanide on the rate of degra-
dation of verdoheme in complexwith rHO-1with theNADPH/
FMN-depleted CPR system. Fig. 4D shows the time-dependent
absorbance changes at 688 nm of the verdoheme-rHO-1 com-
plex, clearly indicating that the verdoheme degradation was
inhibited by ferricyanide.
A somewhat worrying possibility is that the FMN-deleted
CPRmay generate a relatively larger amount ofH2O2 compared
with wild-type CPR, leading to accelerated conversion of ver-
doheme to biliverdin-iron chelate. Indeed, Matsui et al. (12)
reported that H2O2 is an alternative and more efficient oxygen
source than O2 for verdoheme degradation to biliverdin under
anaerobic conditions. In our aerobic reaction conditions with
wild-type CPR or the FMN-depleted CPR and NADPH, the
amount of H2O2 generated was at most 1 M over a 60-min
incubation (supplemental Table S2). Further, aerobic incuba-
FIGURE 4. Absorption spectral changes of the verdoheme-rHO-1 complex during the NADPH/CPR-sup-
ported single turnover reaction. The spectra were recorded before (thin solid line) and after the addition of
NADPH (dotted line, 1 min; dashed line, 10 min; thick solid line, 30 min; dotted and dashed line, 60 min). The
procedures are described under “Experimental Procedures.” A, with wild-type CPR; B, with FMN-depleted CPR.
C, FMN-depleted CPR-dependent verdoheme degradation. The rate of degradation of verdoheme in complex
with rHO-1 was calculated from the decrease of the absorbance at 399 nm. D, effect of ferricyanide on the
FMN-depleted CPR-dependent degradation of verdoheme. Time-dependent absorbance changes at 688 nm
were plotted in the reaction with 5 M verdoheme-rHO-1 complex, 100 nM FMN-depleted CPR, 25 M NADPH
in the presence of 0 (open circle), 50 (closed triangle), 60 (open triangle), and 100 M (closed circle) ferricyanide.
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tion of the verdoheme-rHO-1 complex with H2O2 (1 M)
caused nonproductive decomposition of verdoheme, not lead-
ing to biliverdin-iron chelate or biliverdin formation (supple-
mental Fig. S2), as reported previously (12).
These findings obtained with the FMN-depleted CPR
indicate that electrons are certainly required for conversion
of verdoheme to the ferric biliverdin-iron chelate and that
they can be supplied by the FMN-depleted CPR without the
involvement of FMN. The final electron, however, to reduce
ferric biliverdin and release ferrous iron and biliverdin
should be provided by FMN.
Single Turnover Reactions of the FePPDME-rHO-1 Com-
plex—As mentioned above, the electrostatic interactions
between the highly conserved basic residues, Lys179 andArg183,
and the heme propionates are crucial not only for the proper
accommodation of heme in the heme pocket but also for elec-
tron transfer between CPR and HO. To probe this, we con-
structed the FePPDME-rHO-1 complex and examined its sin-
gle turnover reactions.
The optical spectra of the ferric, ferrous, and CO-bound
forms of FePPDME-rHO-1 complex (supplemental Fig. S3)
were very similar to those of the heme-rHO-1 complex (33),
suggesting that the modifications of the heme propionate
groups do not significantly affect the proximal histidine ligation
and heme environment in the heme pocket.
First a single turnover reaction of the FePPDME-rHO-1
complex was carried out within the ascorbate-supported sys-
tem. FePPDME complexed with rHO-1 decomposed to a spe-
cies with a weak broad band around 800 nm (Fig. 6A). In order
to confirm it as the iron chelate of biliverdin dimethyl ester,
desferrioxaminewas added to the reactionmixture 20min after
initiation. As shown in Fig. 6B, a broad absorption band
appeared around 650 nm, indicative of formation of biliverdin
dimethyl ester. The amount of biliverdin dimethyl ester was
comparable with the amount of FePPDME-rHO-1 complex
employed.
In a single turnover reaction of FePPDME-rHO-1 complex
with the NADPH/wild-type CPR-supported system, the inten-
sity of the Soret band decreased and red-shifted to 409 nm
within 1 min and then further decreased with time (Fig. 7A). In
the visible region, new absorption peaks at 537 and 573 nm
corresponding to the oxy form of the FePPDME-rHO-1 com-
plex appeared within 1 min, and they decreased along with the
appearance of a new well resolved peak at 628 nm and a shoul-
der around 670 nm after 5 min. Thereafter, the absorbance in
the 500–700-nm regions gradually decreased. With an excess
of NADPH (200 M), identical spectral changes were observed
(data not shown). The addition of desferrioxamine to the reac-
tion mixture 40 min after the reaction began produced a small
broad absorption band around 650 nm, indicating that only a
FIGURE 5. Absorption spectral changes of the ferric biliverdin-iron che-
late complex of rHO-1 during the NADPH/CPR-supported single turn-
over reaction. The verdoheme-rHO-1 complex (5 M) was incubated with
NADPH (25M) and FMN-depleted CPR (0.08M). After 60min, desferrioxam-
ine (2mM) (A) orwild-typeCPR (0.04M) (B)was added to themixture. Spectra
before (thin solid line) and after the addition of desferrioxamine or wild-type
CPR (dotted line, 1 min; dashed line, 10 min; thick solid line, 30 min) were
monitored.
FIGURE 6. Absorption spectral changes of FePPDME-rHO-1 complex dur-
ing theascorbate-supported single turnover reaction.A, the spectrawere
recorded before (thin solid line) and after the addition of 20 mM ascorbate
(dottedanddashed line, 1min;dotted line, 9min;dashed line, 39min; thick solid
line, 139 min) to the solution of FePPDME-rHO-1 complex (5 M) in 0.1 M
potassium phosphate buffer (pH 7.4). B, desferrioxamine was added to the
reaction mixture at 20 min after the addition of ascorbate. Spectra before
(dotted line) and after the addition of desferrioxamine (thin solid line, 3 min;
dashed line, 9 min; thick solid line, 39 min) were monitored.
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part of the FePPDME-rHO-1 complex employedwas converted
to free biliverdin dimethyl ester in this system (Fig. 7B). The
accumulated intermediate, showing a sharp peak at 628 nm
with a shoulder around 670 nmwas confirmed to be verdoheme
dimethyl ester complexed with rHO-1 by repeating evacuation
and flushing with N2 gas and introducing CO (supplemental
Fig. S4). The gradual decrease of the absorbance between 600
and 700 nm observed during the single turnover reaction of
FePPDME-rHO-1 complex with the NADPH/wild-type CPR-
supported system (Fig. 7A) was partly due to nonproductive
decomposition of the verdoheme species by O2 (8, 12).
HPLC analyses revealed that the biliverdin dimethyl es-
ters produced in the single turnover reaction of the FePP-
DME-rHO-1 complex in the NADPH/wild-type CPR-sup-
ported reaction were 16.6  3.5% biliverdin IX dimethyl
ester, 5.4 0.5% IX, and 78.0 3.8% IX, and in the ascor-
bate-supported reaction, they were 28.7  3.2% biliverdin
IX dimethyl ester, 4.9  0.9% IX, 1.2  0.3% IX, and
65.2 4.1% IX. The observed regioisomer ratios of biliver-
din dimethyl ester in the NADPH/wild-type CPR- and ascor-
bate-supported reactions are similar to those found with the
K18E/R183E double mutant of human HO-1 (30), in which
the electrostatic interactions between Lys18 or Arg183 and
heme propionates are probably weakened. Although the
-regiospecificity was lost in the FePPDME-rHO-1 complex,
it should be noted that verdoheme dimethyl ester isomers
accumulated in the CPR-supported reaction but not in the
ascorbate-supported reaction.
DISCUSSION
In this study, we succeeded in preparing FMN-depleted CPR
from the Y140A/Y178Amutant using the KBrmethod (35, 38).
This depleted enzyme lost its ability to transfer an electron to
cytochrome c but retained its ferricyanide-reducing activity
(Tables 1 and 2). With the FMN-depleted CPR, we demon-
strated that the degradation of heme in complex with rHO-1
never occurs (Fig. 4B), although the FMN-depleted CPR asso-
ciates with the heme complex of rHO-1 with a binding affinity
comparable with that of wild-type CPR. Thus, the first electron
to reduce the ferric heme to the ferrous state in the HO-1 com-
plex must be transferred from FMN. On the other hand, the
FMN-depleted CPR is capable of serving as an electron donor
to verdoheme in its complex with rHO-1, and indeed it is
degraded to the ferric biliverdin-iron chelate in an FMN-de-
pleted CPR-dependent manner (Fig. 4, B and C). Furthermore,
this reaction is inhibited by the addition of ferricyanide (Fig.
4D), clearly indicating that electrons are required for conver-
sion of verdoheme to the ferric biliverdin-iron chelate, and that
they can be supplied by the FMN-depletedCPR through a path-
way not involving FMN. This conclusion is also supported by
the observation that verdoheme dimethyl esters are accumu-
lated in the single turnover reaction of the FePPDME-rHO-1
complex in the NADPH/wild-type CPR system (Fig. 6A),
although the methylation of heme propionates causes a loss of
-regiospecificity.
Ferric biliverdin-iron chelate, generated by the NADPH/
FMN-depleted CPR system, was converted to biliverdin by the
addition of thewild-typeCPRor desferrioxamine (Fig. 5). Thus,
the final electron for reducing ferric biliverdin-iron chelate to
release ferrous iron and biliverdin is apparently provided by the
FMN of CPR.
The most striking finding of the present study is that the
electrons required for verdoheme oxidation can be supplied
through an alternative pathway not involving FMN. It is rea-
sonable to assume that the most probable electron-donating
site in the FMN-deleted CPR is FAD. Indeed, it has been
reported that partially FAD-deficient CPR shows a decreased
ferricyanide reducing activity (36).
The HO reaction proceeds via a multistepmechanism that is
different from other hemoproteins, such as cytochrome P450s
and cytochrome b5. The alternative electron pathway may
function only for verdoheme degradation, which is considered
to be a rate-limiting step of the HO reaction (12). However,
whether or not this alternative pathway is available in wild-type
CPR remains to be established.We believe that further analysis
of the electron transfer pathway from CPR to HO-1 (e.g.
employing FAD-depleted CPR) and the crystal structure of
CPR-HO-1 complex should address this issue.
Recently, we (19) and the group of Ortiz de Montellano (41)
have identified surface amino acids of HO-1 that are essential
for binding to and/or electron transfer fromCPR and have clar-
ified some important interactions between those amino acid
residues andCPR (Fig. 2). In our dockingmodel of ratHO-1 and
FIGURE 7. Absorption spectral changes of FePPDME-rHO-1 complex dur-
ing the NADPH/CPR-supported single turnover reaction. A, the spectra
were recorded before (thin solid line) and after the addition of NADPH (25M)
(dashedanddotted line, 1min;dotted line, 5min;dashed line, 10min; thick solid
line, 25 min) to the solution of FePPDME-rHO-1 complex (5 M) and wild-
type CPR (0.04 M) in 0.1 M potassium phosphate buffer (pH 7.4). B, desferri-
oxamine was added to the reaction mixture at 40 min after the addition of
NADPH. Spectra before (thick solid line) and after the addition of desferriox-
amine (dashed line, 10 min; thin solid line, 40 min) were monitored.
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rat CPR, there is a close contact between Lys149 in the distal
F-helix of rHO-1 and the acidic cluster near the FMN site of
CPR. In fact, a diminished reduction rate of ferric heme in com-
plex with the rHO-1 mutants K149A or K153A has been
observed (19). In addition, the distal F-helix of rHO-1 contains
Asp140, which participates in the hydrogen bonding network
that provides protons required for the activation ofO2 bound to
heme iron to hydroperoxide (30, 42). Our docking model also
suggests that Arg185 of HO-1, the guanidino group of which
could interact with 2-phosphate of NADPH in CPR, is located
two amino acid residues upstream from Arg183 that interacts
electrostatically with the inner side heme propionate group in
the heme-rHO-1 complex (20, 30).
It has been reported that substitutions of Asp140 in the distal
heme pocket of rat and human HO-1 to Ala or Phe lead to
destabilization of the distal hydrogen bonding network and
completely abolish the first step of HO catalysis, the meso-hy-
droxylation of heme (42–44). Lad et al. (14) have reported the
crystal structure of the ferrous verdoheme-human HO-1 com-
plex, inwhich thewatermolecules, the constituents of the distal
hydrogen bonding network, are missing. Consequently, in the
crystal structure, the verdoheme can no longer interact with
Asp140 through the hydrogen bonding network. However, in
the crystal structure of rHO-1 containing the biliverdin-iron
chelate, there is, in contrast to the structure of the verdoheme-
human HO-1 complex, a hydrogen bonding network with
Asp140, including three water molecules (24). Thus, the confor-
mation of the verdoheme-HO-1 complex surrounding ver-
doheme seems to be fairly distinct from those in the complexes
of HO-1 with heme, -hydroxyheme, or biliverdin-iron chelate
(the crystal structure of-hydroxyheme-HO-1 complex has yet
to be determined). It is tempting to consider that the structural
basis for the alternative electron transfer pathwaymay reside in
the unique conformation of the verdoheme-HO-1 complex, but
it should be noted that one of the propionate groups is also
invisible in the crystal structure of the verdoheme-human
HO-1 complex at 2.2 Å resolution (14). Its crystal structure at
high resolution is awaited with great interest.
Ortiz de Montellano and co-workers (29, 30) have reported
that with the Arg183 mutants of human HO-1, the rate of bili-
rubin formation in the presence of biliverdin reductase and
ascorbate-supported system is little affected but that in the
NADPH/CPR-supported system it is severely diminished. On
the other hand, the double mutants, such as K18E/R183E, of
human HO-1 showed a loss of -regiospecificity, compared
with the wild type in both NADPH/CPR- and ascorbate-sup-
ported systems. In addition, the hydrogen bonding network in
the crystal structure of the heme-R183EHO-1 complexmutant
has been found to be disordered (29). These facts as well as our
findings obtained with FePPDME indicate that the heme pro-
pionate electrostatically interactingwithArg183 not only plays a
role in properly orienting the hemebutmight also participate in
electron transfer from FAD that occurs in the conversion of
verdoheme to the biliverdin-iron chelate.
Acknowledgments—We thankDrs. Keiichi FukuyamaandMasakazu
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Supplemental data 
 
1) CD spectra of wild-type and FMN-depleted CPR 
 
 
 
Fig. S1.  CD spectra of wild-type (–––––) and FMN-depleted CPR (--------).  The CD spectra 
were recorded on a JASCO J-815 spectropolarimeter using a 1-cm path length quartz cell.  Protein 
concentrations were 25 µg/ml in 10 mM potassium phosphate buffer containing 1 mM EDTA, 0.1 mM 
dithiothreitol, pH 7.7.  Data were collected from 260 to 195 nm at 0.5 nm intervals and at a rate of 100 
nm/min with a response time of 2 s for each point.  Spectra were presented as an average of eight 
repeats. 
 
 
Table S1. Secondary structures of wild-type and FMN-depleted CPR  
               secondary structure (%)a
 α-helix β-sheet turn random 
wild-type CPR 36 17 18 29 
FMN-depleted CPR 35 17 19 29 
 
aThe predicted contents of secondary structures were calculated using the SELCON3 program (S1) 
 
26 
2) H2O2-dependent verdoheme degradation 
 
Table S2. Quantification of H2O2 produced by the NADPH/wild-type CPR and the 
NADPH/FMN-depleted CPR systems. 
 
Enzyme Incubation time  H2O2
 min µM a
wild-type CPR 
 
 
 
10 
30 
60 
0.13 
0.63 
1.08 
FMN-depleted CPR 10 
30 
60 
0.14 
0.61 
1.06 
 
aA solution of wild-type or FMN-depleted CPR (40 nM) in 0.1 M potassium phosphate buffer, pH 7.4 was 
incubated with 25 µM NADPH for the indicated period at room temperature in the air.  Quantification of 
H2O2 was performed employing Bindschedler's Green method (S2).  Briefly, 0.2 ml of test solution and 
1.8 ml of color reagent solution containing 0.1 mM N-(carboxymethylaminocarbonyl)-4,4-bis 
(dimethylamino) diphenylamine sodium salt (Wako, Osaka, Japan), 0.1 mM PEPES, pH 7.0, 0.5 % Triton 
X-10 and 1U/ml horseradish peroxidase (Sigma, St. Louis, MO) were incubated for 5 min at 37 °C.  The 
absorbance at 727 nm (ε = 90 mM-1cm-1) was measured. 
27 
 
 
Fig. S2.  Absorption spectral changes of the verdoheme–rHO-1 complex during the incubation 
with H2O2.   (A) The spectra were recorded before (———) and after the addition of H2O2 (1 µM) (10 
min, --------; 30 min, ▬▬▬; and 60 min, −·−·−·−) to the solution of verdoheme-rHO-1 complex (ca. 5 
µM) in 0.1 M potassium phosphate buffer (pH 7.4).  After 60 min, (B) desferrioxamine (2 mM) or (C) 
ascorbate (20 mM) was added to the mixture.  Spectra before (———) and after the addition of 
desferrioxamine or ascorbate (1 min, ···········; 10 min, --------; 30 min, ▬▬▬) were monitored. 
28 
3) Degradation of FePPDME in complex with rHO-1 
 
 
 
Fig. S3.  Optical absorption spectra of FePPDME-rHO-1 complex (ca. 5 µM) in ferric (———), 
ferrous (▬▬▬) and CO-ferrous (···········) forms in 0.1 M potassium phosphate buffer (pH 7.4).  
Its ferrous complex was formed by reduction of the ferric complex with a few grains of sodium dithionite 
and its ferrous carbon monoxide complex was formed by saturating the ferric complex solution with CO 
gas by bubbling for 1 min followed by reduction with a few grains of sodium dithionite. 
29 
 
 
 
Fig. S4.  Spectroscopic characterization of the accumulated intermediates in the 
NADPH/CPR-supported single turnover reaction of FePPDME-rHO-1 complex.  Reaction 
conditions were the same as those shown in Fig. 7.  Solid line(———): The intermediate accumulated 
during first 5 min; Bold line(▬▬▬): After replacing the gas phase with N2 gas; Dotted line(···········): 
After the introduction of CO. 
Additional caption to Fig. S4- The intermediate accumulated, showing a sharp peak at 628 nm with a 
shoulder around 670 nm was confirmed to be verdoheme dimethyl ester in complex with rHO-1.  By 
repeating evacuation and flushing with N2 gas, the sharp peak at 628 nm was decreased and the shoulder 
was increased to show a clear peak at 669 nm.  When CO gas was introduced into the cuvette, the peak 
at 669 nm was decreased and the 628-nm peak was increased again.  Thus it was concluded that the 628- 
and 670-nm species are CO-ferrous and ferrous forms of verdoheme dimethyl ester, respectively. 
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